Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Schofield
Delays in the delivery of medicines with short lead times will be longer than originally expected in the event of a no-deal Brexit, UK health care providers have been warned.
As the Brexit clock continues to tick, industry says it is not impressed by government reassurances that all is well where the continued supply of medicines is concerned.
England’s health technology assessment body has recommended the use of Shire’s orphan drug Takhzyro for use in patients with hereditary angioedema, but only in certain circumstances and provided the company offers the product at the agreed discounted price.
New final guidance from NICE explains how best to avoid the risk of antibiotic resistance in patients with community- and hospital-acquired pneumonia.
Pharmaceutical companies will have a better idea of the conditions under which a supplementary protection certificate can be granted after an advocate general of the European court explained how a new legal test established last year should be used. However, lawyers caution that the opinion still leaves some aspects to be clarified.
The European Pharmacopoeia, which has been updated to reflect regulatory and scientific advances, contains 114 new monographs including substances of “high therapeutic interest.” Holders of CEPs have been advised to update their certificates in line with the new monographs.